专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160333420A1 GENE EXPRESSION PANEL FOR PROGNOSIS OF PROSTATE CANCER RECURRENCE 审中-公开
标题翻译：用于预防癌症复发的基因表达板
公开(公告)号：US20160333420A1
公开(公告)日：2016-11-17
申请号：US15111946
申请日：2015-01-16
申请人： ILLUMINA, INC. , UNIVERSITY OF SOUTHERN CALIFORNIA
发明人： Mariana Carla Stern , Jacek Pinski , Jian-Bing Fan
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： Disclosed is a gene expression panel that can be used to predict prostate cancer (PCa) progression. Some embodiments provide methods for predicting clinical recurrence of PCa. Some embodiments provide a method for predicting progression of prostate cancer in an individual, the method comprising: (a) receiving expression levels of a collection of signature genes from a biological sample taken from said individual, wherein said collection of signature genes comprises at least two genes selected from the group consisting of: NKX2-1, UPK1A, ADRA2C, ABCC11, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, PGC, UPK3B, PCBP3, ABLIM1, EDARADD, GPR81, MYBPC1, F10, KCNA3, GLDC, KCNQ2, RAPGEF1, TUBB2B, MB, DUOXA1, C2orf43, DUOX1, PCA3 and NPR3; (b) applying the expression levels to a predictive model relating expression levels of said collection of signature genes with prostate cancer progression; and (c) evaluating an output of said predictive model to predict progression of prostate cancer in said individual. Systems are also provided for predicting progression and/or recurrence of PCa.
摘要翻译：公开了可用于预测前列腺癌（PCa）进展的基因表达小组。一些实施方案提供了用于预测PCa的临床复发的方法。一些实施方案提供了预测个体中前列腺癌进展的方法，所述方法包括：（a）接收来自所述个体的生物样品的特征基因集合的表达水平，其中所述签名基因的收集包括至少两个选自NKX2-1，UPK1A，ADRA2C，ABCC11，MMP11，CPVL，ZYG11A，CLEC4F，OAS2，PGC，UPK3B，PCBP3，ABLIM1，EDARADD，GPR81，MYBPC1，F10，KCNA3，GLDC，KCNQ2， RAPGEF1，TUBB2B，MB，DUOXA1，C2orf43，DUOX1，PCA3和NPR3; （b）将所述表达水平应用于将所述特征基因集合的表达水平与前列腺癌进展相关联的预测模型; 和（c）评估所述预测模型的输出以预测所述个体中前列腺癌的进展。还提供了用于预测PCa进展和/或复发的系统。

2. 发明申请

US20220033915A1 GENE EXPRESSION PANEL FOR PROGNOSIS OF PROSTATE CANCER RECURRENCE 有权
公开(公告)号：US20220033915A1
公开(公告)日：2022-02-03
申请号：US17405686
申请日：2021-08-18
申请人： Illumina, Inc. , University of Southern California
发明人： Mariana Carla Stern , Jacek Pinski , Jian-Bing Fan
IPC分类号： C12Q1/6886
摘要： Disclosed is a gene expression panel that can be used to predict prostate cancer (PCa) progression. Some embodiments provide methods for predicting clinical recurrence of PCa. Some embodiments provide a method for predicting progression of prostate cancer in an individual, the method comprising: (a) receiving expression levels of a collection of signature genes from a biological sample taken from said individual, wherein said collection of signature genes comprises at least two genes selected from the group consisting of: NKX2-1, UPK1A, ADRA2C, ABCC11, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, PGC, UPK3B, PCBP3, ABLIM1, EDARADD, GPR81, MYBPC1, F10, KCNA3, GLDC, KCNQ2, RAPGEF1, TUBB2B, MB, DUOXA1, C2orf43, DUOX1, PCA3 and NPR3; (b) applying the expression levels to a predictive model relating expression levels of said collection of signature genes with prostate cancer progression; and (c) evaluating an output of said predictive model to predict progression of prostate cancer in said individual. Systems are also provided for predicting progression and/or recurrence of PCa.

3. 发明授权

US11098372B2 Gene expression panel for prognosis of prostate cancer recurrence 有权
公开(公告)号：US11098372B2
公开(公告)日：2021-08-24
申请号：US16524617
申请日：2019-07-29
申请人： Illumina, Inc. , University of Southern California
发明人： Mariana Carla Stern , Jacek Pinski , Jian-Bing Fan
IPC分类号： C12Q1/6886
摘要： Disclosed is a gene expression panel that can be used to predict prostate cancer (PCa) progression. Some embodiments provide methods for predicting clinical recurrence of PCa. Some embodiments provide a method for treating a patient with prostate cancer, the method comprising: detecting expression levels of a collection of signature genes from a biological sample taken from said patient, wherein said collection of signature genes comprises at least NKX2-1; and correlating expression levels of said collection of signature genes with prostate cancer-related mortality to identify whether the patient is at risk of prostate cancer-related mortality.

4. 发明申请

US20200071770A1 GENE EXPRESSION PANEL FOR PROGNOSIS OF PROSTATE CANCER RECURRENCE 审中-公开
公开(公告)号：US20200071770A1
公开(公告)日：2020-03-05
申请号：US16524617
申请日：2019-07-29
申请人： Illumina, Inc. , University of Southern California
发明人： Mariana Carla Stern , Jacek Pinski , Jian-Bing Fan
IPC分类号： C12Q1/6886
摘要： Disclosed is a gene expression panel that can be used to predict prostate cancer (PCa) progression. Some embodiments provide methods for predicting clinical recurrence of PCa. Some embodiments provide a method for predicting progression of prostate cancer in an individual, the method comprising: (a) receiving expression levels of a collection of signature genes from a biological sample taken from said individual, wherein said collection of signature genes comprises at least two genes selected from the group consisting of: NKX2-1, UPK1A, ADRA2C, ABCC11, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, PGC, UPK3B, PCBP3, ABLIM1, EDARADD, GPR81, MYBPC1, F10, KCNA3, GLDC, KCNQ2, RAPGEF1, TUBB2B, MB, DUOXA1, C2orf43, DUOX1, PCA3 and NPR3; (b) applying the expression levels to a predictive model relating expression levels of said collection of signature genes with prostate cancer progression; and (c) evaluating an output of said predictive model to predict progression of prostate cancer in said individual. Systems are also provided for predicting progression and/or recurrence of PCa.

5. 发明授权

US10364469B2 Gene expression panel for prognosis of prostate cancer recurrence 有权
公开(公告)号：US10364469B2
公开(公告)日：2019-07-30
申请号：US15111946
申请日：2015-01-16
申请人： Illumina, Inc. , University of Southern California
发明人： Mariana Carla Stern , Jacek Pinski , Jian-Bing Fan
IPC分类号： C12Q1/6886
摘要： Disclosed is a gene expression panel that can be used to predict prostate cancer (PCa) progression. Some embodiments provide methods for predicting clinical recurrence of PCa. Some embodiments provide a method for predicting progression of prostate cancer in an individual, the method comprising: (a) receiving expression levels of a collection of signature genes from a biological sample taken from said individual, wherein said collection of signature genes comprises at least two genes selected from the group consisting of: NKX2-1, UPK1A, ADRA2C, ABCC11, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, PGC, UPK3B, PCBP3, ABLIM1, EDARADD, GPR81, MYBPC1, F10, KCNA3, GLDC, KCNQ2, RAPGEF1, TUBB2B, MB, DUOXA1, C2orf43, DUOX1, PCA3 and NPR3; (b) applying the expression levels to a predictive model relating expression levels of said collection of signature genes with prostate cancer progression; and (c) evaluating an output of said predictive model to predict progression of prostate cancer in said individual. Systems are also provided for predicting progression and/or recurrence of PCa.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式